13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002026172
Total reported value
$791.3M
$791.3M
111 檔
24.7%
At the close of Q1 2026, Diadema Partners LP disclosed equity holdings valued at approximately $791.3M, spread across 111 reported holdings.
Diadema Partners LP executed strategic sector rebalancing during Q1 2026, establishing 44 new positions while fully exiting 52 holdings and trimming 27 positions.
In terms of portfolio concentration, the top 5 core holdings (including UTHR, VRTX, VKTX) accounted for 24.7% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | Stock-Healthcare | 8.83% | -5.20% | +775.03% | |
| 2 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 7.37% | -7.37% | EXIT | |
| 3 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 6.56% | +3.36% | -11.77% | |
| 4 | CAPR | Capricor Therapeutics Inc | Stock-Other | 5.34% | -2.71% | +53.88% | |
| 5 | ABVX | Abivax Sa-adr | Stock-Other | 5.19% | +7.67% | +264.79% | |
| 6 | LQDA | Liquidia CORP | Stock-Other | 4.57% | -4.57% | EXIT | |
| 7 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.41% | -0.12% | +457.46% | |
| 8 | APGE | Apogee Therapeutics Inc | Stock-Other | 3.19% | -3.19% | EXIT | |
| 9 | BBIO 1.75 03-01-31Bond | Bridgebio Pharma Inc | Bond | 3.16% | -0.81% | — | |
| 10 | INCY | Incyte CORP | Stock-Healthcare | 2.94% | -1.43% | +83.43% | |
| 11 | KOD | Kodiak Sciences Inc | Stock-Other | 2.85% | -0.08% | +1386.70% | |
| 12 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.80% | -2.48% | — | |
| 13 | JNJ | Johnson & Johnson | Stock-Healthcare | 2.24% | -1.53% | -53.82% | |
| 14 | COGT | Cogent Biosciences Inc | Stock-Other | 2.11% | +0.30% | +144.79% | |
| 15 | MRK | Merck & Co. Inc. | Stock-Healthcare | 2.05% | -2.05% | EXIT | |
| 16 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 1.76% | -1.76% | EXIT | |
| 17 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.64% | -1.64% | EXIT | |
| 18 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.63% | -1.63% | EXIT | |
| 19 | QURE | uniQure N.V. | Stock-Other | 1.61% | +1.50% | +67.30% | |
| 20 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 1.58% | -1.58% | EXIT | |
| 21 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.42% | +0.84% | +1.28% | |
| 22 | MRNA | Moderna Inc | Stock-Healthcare | 1.38% | -0.50% | — | |
| 23 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 1.17% | -0.64% | -7.32% | |
| 24 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 1.16% | +1.11% | -27.45% | |
| 25 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.14% | +0.26% | +608.33% | |
| 26 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.08% | -1.08% | EXIT | |
| 27 | REPL | Replimune Group Inc | Stock-Other | 1.00% | +0.68% | +231.63% | |
| 28 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.99% | +0.03% | +174.81% | |
| 29 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.94% | +0.58% | +200.00% | |
| 30 | ABBV | Abbvie Inc | Stock-Healthcare | 0.89% | -0.89% | EXIT | |
| 31 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.89% | +0.22% | — | |
| 32 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.88% | +0.48% | — | |
| 33 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.87% | -0.06% | +561.23% | |
| 34 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.86% | -0.86% | EXIT | |
| 35 | PCVX | Vaxcyte Inc | Stock-Other | 0.77% | +0.31% | +240.29% | |
| 36 | EYPT | Eyepoint Inc | Stock-Other | 0.62% | -0.43% | — | |
| 37 | ZYME | Zymeworks Inc | Stock-Other | 0.61% | -0.14% | -45.75% | |
| 38 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.52% | +0.24% | +200.75% | |
| 39 | ALMS | Alumis Inc | Stock-Other | 0.49% | +0.22% | — | |
| 40 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.49% | +0.07% | -26.09% | |
| 41 | ANNX | Annexon Inc | Stock-Other | 0.46% | -0.19% | -26.25% | |
| 42 | BHVN | Biohaven Ltd. | Stock-Other | 0.46% | +0.14% | +58.50% | |
| 43 | CELC | Celcuity Inc | Stock-Other | 0.45% | -0.19% | — | |
| 44 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.44% | -0.32% | +1138.19% | |
| 45 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 0.44% | +0.51% | +32.73% | |
| 46 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.44% | -0.01% | -62.21% | |
| 47 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.38% | -0.13% | — | |
| 48 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.38% | -0.13% | — | |
| 49 | INDV | Indivior Pharmaceuticals Inc | Stock-Other | 0.37% | -0.02% | — | |
| 50 | CLYM | Climb Bio Inc | Stock-Other | 0.33% | -0.33% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | +8% | +775.03% | Add |
| 2 | LQDA | Liquidia CORP | +4.4% | +3154.42% | Add |
| 3 | ABVX | Abivax Sa-adr | +3.4% | +264.79% | Add |
| 4 | RVMD | Revolution Medicines Inc | +2.9% | +457.46% | Add |
| 5 | KOD | Kodiak Sciences Inc | +2.7% | +1386.70% | Add |
| 6 | CAPR | Capricor Therapeutics Inc | +2% | +53.88% | Add |
| 7 | COGT | Cogent Biosciences Inc | +1.3% | +144.79% | Add |
| 8 | INCY | Incyte CORP | +1.2% | +83.43% | Add |
| 9 | EWTX | Edgewise Therapeutics Inc | +1% | +608.33% | Add |
| 10 | CRVS | Corvus Pharmaceuticals Inc | +0.8% | +561.23% | Add |
| 11 | REPL | Replimune Group Inc | +0.6% | +231.63% | Add |
| 12 | PCVX | Vaxcyte Inc | +0.6% | +240.29% | Add |
| 13 | IMCR | Immunocore Holdings Plc-adr | +0.6% | +174.81% | Add |
| 14 | LLY | Eli Lilly & Co | +0.6% | +200.00% | Add |
| 15 | APGE | Apogee Therapeutics Inc | +0.5% | +5.40% | Add |
| 16 | ROIV | Roivant Sciences Ltd. | +0.4% | +5.37% | Add |
| 17 | HRMY | Harmony Biosciences Holdings | +0.4% | +1138.19% | Add |
| 18 | GLUE | Monte Rosa Therapeutics Inc | +0.4% | +200.75% | Add |
| 19 | QURE | uniQure N.V. | +0.2% | +67.30% | Add |
| 20 | AVXL | Anavex Life Sciences CORP | +0.2% | +239.69% | Add |
| 21 | BHVN | Biohaven Ltd. | +0.1% | +58.50% | Add |
| 22 | IVA | Inventiva SA - Adr | +0.1% | +5.43% | Add |
| 23 | EQ | Equillium Inc | +0.1% | +24.89% | Add |
| 24 | FHTX | Foghorn Therapeutics Inc | 0% | +161.00% | Add |
| 25 | TGTX | Tg Therapeutics Inc | 0% | -7.32% | Trim |
| 26 | AYTU | Aytu Biopharma Inc | 0% | +15.46% | Add |
| 27 | JANX | Janux Therapeutics Inc | — | +5.33% | Add |
| 28 | INO | Inovio Pharmaceuticals Inc | — | +0.66% | Add |
| 29 | ATYR | Atyr Pharma Inc | — | -9.52% | Trim |
| 30 | JBIO | Jade Biosciences Inc | — | — | Unchanged |
| 31 | VTGN | Vistagen Therapeutics Inc | 0% | -48.95% | Trim |
| 32 | ✓ | Proqr Therapeutics N.v. | 0% | +7.49% | Add |
| 33 | TLPH | Talphera Inc | 0% | +12.15% | Add |
| 34 | LYEL | Lyell Immunopharma Inc | 0% | +7.89% | Add |
| 35 | PRTCY | Puretech Health PLC - Adr | 0% | +6.48% | Add |
| 36 | URGN | UroGen Pharma Ltd. | 0% | +6.17% | Add |
| 37 | TENX | Tenax Therapeutics Inc | 0% | -26.09% | Trim |
| 38 | NVO | Novo-nordisk A/s-spons Adr | 0% | +32.73% | Add |
| 39 | PTHS | Pelthos Therapeutics Inc | 0% | -0.91% | Trim |
| 40 | ENTA | Enanta Pharmaceuticals Inc | 0% | -0.29% | Trim |
| 41 | MLYS | Mineralys Therapeutics Inc | 0% | +5.39% | Add |
| 42 | EOLS | Evolus Inc | -0.1% | +5.39% | Add |
| 43 | VIR | Vir Biotechnology Inc | -0.1% | -53.07% | Trim |
| 44 | SLS | Sellas Life Sciences Group I | -0.1% | -29.40% | Trim |
| 45 | UPB | Upstream Bio Inc | -0.1% | +5.41% | Add |
| 46 | RLMD | Relmada Therapeutics Inc | -0.1% | -48.42% | Trim |
| 47 | BMRN | Biomarin Pharmaceutical Inc | -0.1% | +1.28% | Add |
| 48 | XERS | Xeris Biopharma Holdings Inc | -0.1% | -22.17% | Trim |
| 49 | ANNX | Annexon Inc | -0.1% | -26.25% | Trim |
| 50 | CRMD | Cormedix Inc | -0.1% | +5.35% | Add |
According to official SEC Form 13F filings, Diadema Partners LP reported a total U.S. public equity portfolio value of $791.3M across 111 disclosed positions in Q1 2026.
During Q1 2026, Diadema Partners LP's top holdings by market value included UTHR (8.8%)、VRTX (7.4%)、VKTX (6.6%). The largest single position, UTHR, represented 8.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
BBIO 1.75 03-01-31
市值: $18.6M
Top Position Liquidated / Trimmed
XBI
前期市值: $30.5M
In Q1 2026, Diadema Partners LP made 162 total portfolio adjustments, initiating 44 new buys, adding to 39 positions, trimming 27 holdings, and fully liquidating 52 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.